Dave Rosa, President and CEO NeuroOne (OTCQB:NMTC) is developing high-definition, minimally invasive thin-film electrodes for the diagnosis and treatment of various neurological conditions, including epilepsy...
THIS WEEK'S FEATURE
MORE FEATURES
NEWS
HCW ups electroCore PT to $2.50 from $1.50
H.C. Wainwright raised its price target for electroCore (NASDAQ:ECOR) to $2.50 from $1.50, citing the FDA’s emergency use authorization of gammaCore, the company’s lead product, to treat COVID-19 patients. The stock...
Imagin Medical to test i/Blue Imaging System on anatomical bladder models
Imagin Medical (CSE:IME; OTCQB:IMEXF; Frankfurt & Stuttgart Symbol:DPD2) will use anatomical bladder models to confirm the i/Blue Imaging System’s simultaneous white and blue light image display. The anatomical...
Neuronetics names Keith Sullivan as president and CEO
Neuronetics (NASDQ:STIM) appointed Keith Sullivan as president and CEO, effective immediately. Christopher Thatcher, the company’s previous president and CEO, resigned in March 2020. Mr. Sullivan has more than three...
Rigel Pharma fostamatinib being evaluated in COVID-19 pneumonia trial
Rigel Pharmaceuticals’ (NASDAQ:RIGL) fostamatinib is being evaluated in an investigator-sponsored study for the treatment of COVID-19 pneumonia. Fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, is approved...
Histogen completes enrollment in Phase 1b/2a alopecia trial
Histogen (NASDAQ:HSTO) completed patient enrollment in its Phase 1b/2a clinical trial evaluating HST 001 for the treatment of androgenic alopecia in men. The trial enrolled 36 subjects with male pattern hair loss who...
Verrica Pharma gets complete response letter for molluscum contagiosum drug
The FDA issued Verrica Pharmaceuticals (NASDAQ:VRCA) a complete response letter (CRL) regarding the company’s NDA for VP-102. VP-102 is a topical cantharidin solution designed to treat molluscum contagiosum, a viral...
Akebia vadadustat being evaluated for COVID-19-related acute respiratory distress syndrome
Akebia Therapeutics’ (NASDAQ:AKBA) vadadustat is being evaluated in an investigator-sponsored study as a potential therapy to prevent and lessen the severity of COVID-19-related acute respiratory distress syndrome...
Albireo Pharma enrolls first patient in Phase 3 biliary atresia trial
Albireo Pharma (NASDAQ:ALBO) enrolled the first patient in its Phase 3 BOLD clinical trial of odevixibat for the treatment of biliary atresia. Odevixibat is an inhibitor of the ileal bile acid transporter and is...
BTIG slashes NextCure PT to $27 from $61
BTIG more than halved the price target for NextCure (NASDAQ:NXTC) to $27 from $61 after the company announced that its NC318 immunoncology antibody would not be moving forward into stage 2 of the Simon-2-stage trial in...
SVB Leerink cuts Benefytt Technologies to MP; PT up to $31 from $27.50
SVB Leerink downgraded Benefytt Technologies (NASDAQ:BFYT) to “market perform” from “outperform” but raised its price target to $31 from $27.50 after Madison Dearborn Partners agreed to acquire Benefytt for $31 a share...
BTIG cuts Gritstone Oncology PT to $17 from $31
BTIG reduced its price target for Gritstone Oncology (NASDAQ:GRTS) to $17 from $31, citing interim results from two Phase 1 clinical trials, GRANITE and SLATE, evaluating personalized and off-the-shelf neoantigen...
BioSig subsidiary begins enrollment in Phase 2 COVID-19 trial
ViralClear Pharmaceuticals, a subsidiary of BioSig Technologies (NASDAQ: BSGM), began enrolling patients in its Phase 2 clinical trial of merimepodib for the treatment of COVID-19. Merimepodib is an orally...
Just a few of the companies we’ve highlighted along the way
